Perimed

Executive Summary

Perimed is a Swedish medical device and diagnostics company specializing in non-invasive vascular assessment technologies. Founded in 1981, the company leverages laser Doppler and laser speckle contrast imaging to provide real-time measurements of blood perfusion and tissue oxygenation. Its solutions are used by clinicians and researchers for the diagnosis, treatment, and research of peripheral artery disease (PAD) and diabetic foot complications. Perimed has a long track record in the vascular diagnostics field and is well-regarded for its non-invasive, accurate monitoring capabilities. Despite being a private company with limited public disclosures, its established product portfolio and niche market position make it a potential target for strategic partnerships or acquisitions in the medtech space. Perimed's growth prospects are tied to the increasing prevalence of diabetes and peripheral vascular diseases, which drive demand for non-invasive diagnostic tools. The company's proprietary imaging technology offers advantages in early detection and patient monitoring. However, as a private company without recent funding rounds or clinical trial disclosures, near-term visibility is limited. Key potential catalysts include expansion into new geographic markets, FDA clearances for additional indications, or collaborations with larger healthcare companies seeking to enhance their vascular diagnostics offerings.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for next-generation laser speckle contrast imager70% success
• TBDStrategic partnership with a major cardiovascular device company50% success
• Q2 2027Publication of pivotal clinical study demonstrating improved outcomes in diabetic foot ulcer management60% success